Peptide Side Effects: Safety Data from Published Research

Every compound has a safety profile, including research peptides. However, when it comes to peptide safety, we rely primarily on animal studies and do not have sufficient information from the larger human studies necessary for proving the safety of FDA drugs. This guide provides the information available in published studies about peptide side effects, highlighting both strong areas of knowledge and the gaps in information that exist.

What Published Research Reports on Peptide Safety

BPC-157 Toxicology Data

BPC-157 has the most favorable published safety profile of any research peptide. A 2018 review in Current Pharmaceutical Design noted that across all published studies, no lethal dose (LD50) has been established for BPC-157, meaning researchers have not been able to identify a dose high enough to cause death in test animals. Studies using doses up to 100 times the proposed effective dose reported no organ toxicity or lethal effects. However, this toxicology data comes exclusively from rodent models with study durations under 72 days.

TB-500 and Thymosin Beta-4 Safety

Thymosin Beta-4 (the parent compound of TB-500) has undergone human clinical studies aimed at weighing its efficacy of healing wounds, especially cornea injuries. 2012 review in Annals of the New York Academy of Sciences has summarized that results from early clinical studies involving Thymosin Beta-4 showed good tolerability. Observed effects of TB-500 in animal study included mild red marks on the area of injection and a localized swelling of the tissue. However, no organ toxicity has been reported at the doses that are usually applied in standard studies.

Growth Hormone Secretagogue Side Effects

Ipamorelin, CJC-1295 and Tesamorelin trigger the release of growth hormone (GH), which has an established set of possible consequences. Tesamorelin's FDA label indicates side effects such as peripheral edema, joint discomfort, injection site reactions, and increased blood sugar levels. Reports from Phase II Ipamorelin studies highlight similar tendencies, including edema and, at high doses, joint stiffness. These side effects match the rise in GH and IGF-1 concentrations.

Nootropic Peptide Observations

Semax and Selank are clinically used in Russia, where they are authorized for specific neurological applications. According to available human studies of Semax, the common side-effect of nasal irritation is reported with the method of intranasal delivery. Research on Selank has reported both anti-anxiety effects at standardized doses and minimal incidents of side effects. The safety data of both drugs from clinical practices in Europe and America is limited and so their safety profile is based mainly on Russian studies and the data from animal research published in international journals.

Common Observations Across Peptide Studies

Injection Site Reactions

The most frequently encountered observations in peptide research concerning all types of compounds are redness, slight swelling and transient itching at the site of injection. These observations are indicative of the normal bodily response to subcutaneous injecting of any type of liquid substance and are not limited to peptides. Some of the ways to eradicate these affects from mentioned protocols include the correct injection technique such as the change of injection sites, choice of proper size of the needle and good sterilization.

Transient Discomfort

According to certain accounts, minor adverse effects such as nausea, dizziness, or fatigue could occur after administering peptide injections. Animals studies that were published do not systematically examine these subjective outcomes, so the knowledge is mostly from reports provided by persons who used the treatment outside of clinical trials. In the absence of controlled studies, the effects of peptide remain indistiguishable from nocebos, coincidences, or contamination in self-reported data.

Water Retention with GH Peptides

Growth hormone secretagogues (Ipamorelin, CJC-1295, tesamorelin) work to stimulate the amount of growth hormone and insulin-like growth factor 1 in the body, which can lead to water retention. There are reports in published tesamorelin data of swelling in the peripheral limbs of a few patients in the study group. This is a pharmacological effect of the increased level of growth hormone rather than a toxic reaction, and it is determined by the dosage.

Contraindications Discussed in the Literature

Cancer History and Growth Factor Concerns

BPC-157 stimulates vascular endothelial growth factor (VEGF) and additional growth factors responsible for developing blood vessels and cell multiplication. The only theoretical idea is that the substances which activate angiogenesis and cell multiplication could lead to tumor vascularization or growth in individuals with active or hidden neoplasms. No studies that confirm or refute BPC-157 use in oncology are available. At the same time, growth hormone secretagogues stimulate IGF-1 production, which is thought to be responsible for tumor development according to some epidemiological studies. So this is a theoretical contraindication, but it is widely reported in reports about growth-factor-altering compounds.

Pregnancy and Pediatric Exclusions

As far as I know, none of the available articles on the subject have investigated any research peptide on animals that are pregnant or involved in pediatric models for the purpose of testing safety concerning fertility and development. In preclinical research, it is typical to exclude substances for which there is no information on reproductive toxicity, assuming that those substances cannot be used during pregnancy unless it is proved that they are safe for use during gestation period.

Drug Interaction Gaps

Pet studies that involve peptide are being performed on healthy animals that do not consume other drugs at the same time. In fact, as of now, published studies that highlight the possible interactions between peptides and medications, such as anticoagulants, NSAIDs, antihypertensive medicines, immunosuppressants, drugs used in chemotherapy and the ones applied in diabetes treatment, do not exist. This is a major gap in the data available on safety issues.

The Missing Data Problem

No Long-Term Human Safety Studies

The biggest limitation of peptide safety data is that there is no long-term human studies available. Tesamorelin has years’ worth of safety data, obtained from the FDA approval program, but peptides like BPC-157, TB-500, Epithalon, MOTS-c, and others have no human safety studies available, except for anecdotal evidence. A good safety profile in animal testing for 72 days does not guarantee safety in humans over a longer period of time.

Reporting Bias in Self-Reported Data

The vast majority of human experience with research peptides is found in online discussions, social media, and vendor testimonials. This data suffers from serious bias, those witnessing positive effects are much more likely to report it than those who do not notice anything or those who had negative effects possibly do not associate them with the peptide and/or decide not to share them publicly. While self-reported data can be useful for formulating hypotheses, it cannot substitute controlled clinical trials.

How to Evaluate Safety Claims

Animal Data Does Not Equal Human Safety

An example of how a compound that is not toxic in rats could end up being harmful to humans is found in the fact that there are differences in metabolism, distribution of receptors, immune mechanisms, and the physiology of the organ itself. On the contrary, there are cases when harmful compounds to animals are completely harmless to people. Consequently, in order to move from safety in animals to safety in humans, it is essential to carry out full-scale clinical trials with the monitoring needed, which is exactly the sort of thing not available for most research peptides today.

Dose Scaling Between Species

The FDA uses allometric scaling factors for interspecies dose conversion based on body surface area instead of body weight. This has significant implications for understanding the relationship between doses used in animal studies and doses that might work in humans.